Skip to main navigation

Skip to Content

Home
About Us
Clinical Pipeline
- DA-1241
- DA-1726
- Gemcabene
- ANA001
- NB-01
- NB-02
Investors & News
Contact Us

Press Releases

Keyword Search

Year

Sep 15, 2023

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Aug 14, 2023

NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT

Aug 09, 2023

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 03, 2023

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

Aug 02, 2023

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

Jun 27, 2023

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models

Jun 13, 2023

NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions

May 12, 2023

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

May 02, 2023

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Apr 03, 2023

NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Pagination

Current page 1
Page 2
Next page
Last page

Print

RSS Feeds

E-mail Alerts

IR Contacts

LinkedIn
Contact Us
Terms of Use
Privacy Policy

©2023 NeuroBo Pharmaceuticals, Inc.